June 03, 2019
Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019:
- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2019
- Events
- Inside Information
- Latest Inside Information
- Archive Overview
- Inside Information 2019
- Inside Information 2018
- Inside Information 2017
- Ad-hoc 2016
- Ad-hoc 2015
- Ad-hoc 2014
- Ad-hoc 2013
- Ad-hoc 2012
- Ad-hoc 2011
- Ad-hoc 2010
- Ad-hoc 2009
- Ad-hoc 2008
- Ad-hoc 2007
- Ad-hoc 2006
- Ad-hoc 2005
- Ad-hoc 2004
- Ad-hoc 2003
- Ad-hoc 2002
- Ad-hoc 2001
- Ad-hoc 2000
- Ad-hoc 1999
- Ad-hoc 1998
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2019
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Investor News
May 31, 2019
Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Bayer's darolutamide plus androgen deprivation therapy (ADT) delays worsening of disease-related symptoms and maintains quality of life beyond end of study treatment compared to placebo plus ADT in men with non-metastatic castration-resistant prostate can
moreMay 15, 2019
Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019
New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastases
moreMay 13, 2019
Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting:
Bayer to present new data at ASCO 2019 highlighting commitment to evolve cancer treatment paradigm
moreApril 29, 2019
Not intended for U.S. and UK Media
U.S. FDA accepts new drug application and grants priority review for darolutamide
moreApril 29, 2019
Not intended for U.S. and UK Media
Study reaffirms safety and efficacy profile of Xarelto™ for the prevention of stroke in patients with atrial fibrillation
moreApril 27, 2019
After Annual Stockholders' Meeting votes to not ratify Board of Management's actions:
Bayer's Supervisory Board unanimously stands behind Board of Management
moreApril 26, 2019
CEO Werner Baumann at the Annual Stockholders' Meeting of Bayer AG: